# Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
Canonical URL: https://biopharmsignal.com/news/IRON/disc-medicine-appoints-lisa-amaya-price-mba-as-chief-human-resources-officer
Ticker: IRON
Company: Disc Medicine
Source: Disc Medicine
Published: 2026-01-12 21:30 EST
Original Source URL: https://ir.discmedicine.com
## Summary

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the

## Article Body
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the
## Recent Company News
- 2026-06-02 12:00 EST — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-01 12:30 EST — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine
- 2026-05-12 13:30 EST — [Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress) — Source: Disc Medicine
- 2026-05-05 12:30 EST — [Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/IRON/disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Disc Medicine
- 2026-04-21 14:00 EST — [Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)